Nextensa obtains permit for Lake Side project NON-REGULATED INFORMATION Brussels, 02/04/2026 Nextensa obtains permit for Lake Side project Nextensa obtained the urban planning permit for the Lake Side project on 2 April 2026, marking the final phase of the sustainable urban development of the Tour & Taxis site. The approval confirms that the project meets all requirements and represents a milestone in the development of the last zone. The granting of the permit follows a permitting process that began in March 2023. After addressing the requirements formulated by two consultation committ...
Nextensa obtient le permis pour le projet Lake Side INFORMATION NON-RÉGLEMENTÉE Bruxelles, 02/04/2026 Nextensa obtient le permis pour le projet Lake Side Nextensa a obtenu, le 2 avril 2026, le permis d’urbanisme pour le projet Lake Side, dernière phase du développement urbain durable du site de Tour & Taxis. Cette approbation confirme que le projet répond à l’ensemble des conditions et constitue une étape importante pour le développement de la dernière zone. L’octroi du permis fait suite à une procédure entamée en mars 2023. Après avoir répondu...
Nextensa bekomt vergunning voor Lake Side project NIET-GEREGLEMENTEERDE INFORMATIEBrussel, 02/04/2026 Nextensa bekomt vergunning voor Lake Side project Nextensa heeft op 2 april 2026 de stedenbouwkundige vergunning bekomen voor het Lake Side project, het sluitstuk van de duurzame stadsontwikkeling op de Tour & Taxis site. De goedkeuring bevestigt dat het project voldoet aan alle voorwaarden en vormt een mijlpaal voor de ontwikkeling van de laatste zone. Het toekennen van de vergunning volgt op een vergunningsprocedure die in maart 2023 begon. Na het beantwoorden van de eisen die werde...
The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
Nextensa NV/SA: Information on the total number of voting rights and shares PRESS RELEASE REGULATED INFORMATION Brussels, 31 March 2026, 5:55 PM Nextensa NV/SA: Information on the total number of voting rights and shares In application of article 15 of the Law of 2 May 2007 on disclosure of major shareholdings, Nextensa (the 'Company') announces the following information following the loss of double voting rights attached to registered shares. Situation on 31 March 2026: Total capital : EUR 111,856,017.40 Total nu...
Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions COMMUNIQUÉ DE PRESSE INFORMATION RÉGLEMENTÉE Bruxelles, 31 mars 2026, 17h55 Nextensa SA: Informations relatives au nombre total de droits de vote et d'actions En application de l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nextensa (la ‘Société’) communique les informations suivantes suite à la perte des droits de vote double attachés aux actions nominatives. Situation au 31 mars 2026 : Total du...
Nextensa NV: Informatie betreffende het totale aantal stemrechten en aandelen PERSBERICHT GEREGLEMENTEERDE INFORMATIEBrussel, 31 maart 2026, 17u55 Nextensa NV: Informatie betreffende het totale aantal stemrechten en aandelen In toepassing van artikel 15 van de wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen, maakt Nextensa (de ‘Vennootschap’) de volgende informatie bekend naar aanleiding van het verlies van het dubbel stemre...
UCB announced that the European Commission approved Kygevvi (doxecitine and doxribtimine) under exceptional circumstances as the first and only treatment for paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. The approval comes after the positive CHMP opinion announced in February 2026. Beyond the EU, the product received FDA approval in the US in 4Q25. € 284 TP and BUY maintained.
UCB presented updated data for Bimzelx in hidradenitis suppurativa (HS) and psoriasis (PsO) at the AAD conference, held 27–31 March. In HS, data showing better outcomes in patients with lower disease duration and severity makes the case for earlier treatment with Bimzelx, further supporting the drug's continued commercial uptake. In PsO, we're encouraged to see high rates of complete skin clearance up to 4 years in patients that stopped and re-started treatment, which should help UCB capture re-...
We reiterate our BUY rating but cut our target price from €310 to €306, reflecting an increased equity risk premium due to the war in Iran. We continue to view UCB as a unique growth story in the industry, as we model core EPS to grow at c.30% CAGR over 2024-30F thanks to the continued growth of key blockbusters Bimzelx and Evenity. Next to these, we remain confident in UCB's long-term growth strategy with assets like Galvokimig, which continues to show efficacy data optically superior to other ...
Yesterday after market close, UCB announced that it has selected Gwinnett County, Georgia as the location for its new US biologics manufacturing facility. Once operational, the facility is expected to produce recently approved and future pipeline complex biologics 24/7 primarily for the US market. This project is expected to generate approx. $5bn in total economic impact, creating around 330 permanent highly skilled jobs, and more than 1000 construction jobs. Approx. 62% of the company's FY25 ne...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.